MARKET

PDLI

PDLI

PDL BioPharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.480
+0.010
+0.29%
After Hours: 3.480 0 0.00% 16:00 02/21 EST
OPEN
3.490
PREV CLOSE
3.470
HIGH
3.490
LOW
3.420
VOLUME
947.01K
TURNOVER
--
52 WEEK HIGH
3.890
52 WEEK LOW
2.060
MARKET CAP
397.36M
P/E (TTM)
-125.1799
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PDLI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PDLI stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.

EPS

PDLI News

More
  • Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal
  • Zacks · 01/29 16:11
  • AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
  • Zacks · 01/28 15:39
  • Lower prices take shine off Petra Diamonds revenue
  • MarketWatch · 01/27 15:43
  • Axsome (AXSM) Completes Patient Randomization in TRD Study
  • Zacks · 01/23 14:34

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About PDLI

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
More

Webull offers kinds of PDL BioPharma Inc stock information, including NASDAQ:PDLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PDLI stock news, and many more online research tools to help you make informed decisions.